MedTrace Logo

Entyvio (Vedolizumab) Long Term Safety Study

NCT02674308 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5302

Last updated 2024-10-31

No results posted yet for this study

Summary

The purpose of this study is to assess the long-term safety of vedolizumab versus other biologic agents in participants with Ulcerative Colitis (UC) or Crohn's Disease (CD).

Conditions

  • Ulcerative Colitis and Crohn's Disease

Interventions

DRUG

Vedolizumab

OTHER

Other Biologic Agents

Other biologic agents include: Adalimumab, Certolizumab pegol, Golimumab, and Infliximab

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Takeda

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-24
Primary Completion
2021-07-30
Completion
2021-07-30

Countries

  • United States
  • Austria
  • Belgium
  • Canada
  • Croatia
  • Denmark
  • Estonia
  • France
  • Germany
  • Greece
  • Ireland
  • Israel
  • Italy
  • Netherlands
  • Norway
  • Portugal
  • Slovenia
  • Spain
  • Sweden
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02674308 on ClinicalTrials.gov